Outlook Therapeutics receives a buy rating due to a recent FDA appeal victory, improving the probability of US approval for Lytenava. OTLK's near-term upside is driven by regulatory catalysts, despite ongoing concerns about commercial viability and a precarious financial position. Insider buying and a key shareholder's participation in recent offerings signal confidence ahead of binary FDA and Nasdaq compliance catalysts.